Authors' Reply to K. Langdon and Colleagues' Comment on: "Botulinum Toxin in the Management of Children with Cerebral Palsy"

Paediatr Drugs. 2019 Dec;21(6):497-499. doi: 10.1007/s40272-019-00359-1.

Authors

Iqbal Multani¹, Jamil Manji¹, Tandy Hastings-Ison², Abhay Khot³, Kerr Graham⁴

Affiliations

¹ Orthopaedic Department, Royal Children's Hospital, Parkville, VIC, Australia.
² Hugh Williamson Gait Laboratory, Royal Children's Hospital, Parkville, VIC, Australia.
³ Royal Children's Hospital, Parkville, VIC, Australia.
⁴ University of Melbourne, The Royal Children's Hospital, 50 Flemington Road, Parkville, VIC, 3052, Australia. kerr.graham@rch.org.au.

PMID: 31583615
DOI: 10.1007/s40272-019-00359-1

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Botulinum Toxins, Type A*
Cerebral Palsy*
Child
Humans
Muscle Spasticity

Substances

Botulinum Toxins, Type A